Home News

DORIA® presentation

The fast onset of action long-acting injectable of risperidone. Based on our ISM® patented technology.

Wed, 25/10/2017 - 13:50 0 min
Download related document
No votes yet
 
Related
The López-Belmonte family increase their interest in ROVI to 63.1%
The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in...
1 min
27/05/2019
First quarter 2019 results presentation
0 min
08/05/2019
ROVI reports operating revenue growth of 8%, underpinned by outstanding low-...
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 8% to 82.2 million euros in the first quarter of 2019, mainly driven...
5 min
08/05/2019